Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 66,600 shares, a growth of 26.1% from the August 31st total of 52,800 shares. Based on an average daily volume of 52,000 shares, the days-to-cover ratio is […]
Avalo to receive an approximately $15 million upfront payment, up to $74 million in milestone payments.Apollo to lead continued clinical development of.
Avalo Therapeutics (NASDAQ:AVTX – Get Rating) and Puma Biotechnology (NASDAQ:PBYI – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Valuation & Earnings This table compares Avalo Therapeutics and […]
Avalo Therapeutics (NASDAQ:AVTX – Get Rating) announced its earnings results on Thursday. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07), MarketWatch Earnings reports. Avalo Therapeutics had a negative return on equity of 285.61% and a negative net margin of 1,563.10%. Shares of AVTX stock remained flat at […]
Analysts predict that Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) will announce ($0.14) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Avalo Therapeutics’ earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.16). Avalo Therapeutics reported earnings per share of ($0.32) during the same quarter last […]